Please login to the form below

Not currently logged in
Email:
Password:

Bayer's prostate cancer drug fast-tracked

Bayer Healthcare has said its investigational prostate cancer treatment Alpharadin has been fast-tracked for approval by the US Food and Drug Administration (FDA)

Bayer Healthcare has said its investigational prostate cancer treatment Alpharadin (radium-223 chloride), has been fast-tracked for approval by the US Food and Drug Administration (FDA).

The drug, which is licensed from its developers Algeta ASA, is intended for the treatment of castration-resistant prostate cancer in patients with bone metastases.

The FDA's fast track process is designed to accelerate the review of treatments for serious diseases that fill an unmet need. During the process, increased and more frequent communication is encouraged by the FDA, with the extra level of correspondence intended to lead to earlier drug approvals and patient access to treatments.

Dr Kemal Malik, head of global development at Bayer explained there is a "significant unmet need" for patients in advanced stages of the disease.

He said: "We are excited that Alpharadin has achieved this important milestone and recognise this fast track designation as an important step in the overall development of Alpharadin, particularly for those patients in need of treatment."

Bayer holds the global rights to develop and commercialise Alpharadin. However, in the US, Algeta retains an option for co-promotion and profit-sharing.

23rd August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics